Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Zugazagoitia, Jon; Díaz, Asunción; Jiménez, Elisabeth; Núñez, Juan Antonio Vargas; Iglesias, Lara; Paz‐Ares, Luis

doi:10.3389/fmed.2017.00036

Cited by 11 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are inherent differences in active and skin toxicities of the first-generation reversible TKIs, gefitinib, erlotinib and icotinib, the second-generation irreversible TKI, afatinib, and the third-generation TKI, osimertinib, who has activity in patients with T790M-negative acquired resistance (8). Dacomitinib is a novel second-generation, irreversible TKI, which showed potent EGFR signaling inhibition in experimental models, including firstgeneration TKI-resistant NSCLC cell lines (9).…”

Section: Tkismentioning

confidence: 99%

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Peng

Zhang

et al. 2018

BST

View full text Add to dashboard Cite

The past decades have witnessed a rapid increase in the use of molecularly targeted therapies. One class of agents includes the epidermal growth factor receptor inhibitors (EGFRIs), which afford patients longer progression-free survival (PFS) times, especially among non-small cell lung cancer (NSCLC) and metastatic colorectal carcinoma (mCRC). Certain adverse effects, particularly skin toxicity, are mainly manifested as rash, xerosis, pruritus, nails changes, hair changes and mucositis. Previous studies reported the adverse events occurred based on the cutaneous inflammation reaction. Treatment recommended glucocorticoids and antibiotics. It is suggested that skin toxicity is an important issue because it usually affects patients' quality of life (QoL) and still causes dose reduction or discontinuation of targeted therapies. For these reasons, more and more oncologists and dermatologists recognize the importance of recognition and management of skin toxicities with the expansion in availability of EGFRIs. In this review, we conducted a systematic review of recent data to examine the types and frequencies of dermatologic toxicities associated with anti-epidermal growth factor receptor (EGFR) therapies in NSCLC and mCRC. In addition, we would like to explore the management and treatment options currently used by clinicians based on the possible mechanism.

show abstract

Section: Tkismentioning

confidence: 99%

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Peng

Zhang

et al. 2018

BST

View full text Add to dashboard Cite

show abstract

“…It is more potent than afatinib against EGFR sensitizing mutations (del19, L858R). It inhibits both wild type and mutant HER 2 kinase 31 .…”

Section: Dacomitinib (Pf-0299804)mentioning

confidence: 99%

Untitled

2020

IJPSR

View full text Add to dashboard Cite

Lung cancer is a malevolent lung growth characterized by unrestrained cell expansion in tissues of the lung. EGFR is occupied dissimilar fundamental presentation of cancer cells that includes expansion of cells, enlargement, propagation, apoptosis regulation etc. make it a prime objective for lung cancer. EGFR is a tyrosine kinase inhibitor that is proposed in epithelial cells. EGFR inhibitors are drugs that connect to firm parts of EGFR and stop the expansion of cells. Till date, EGFR inhibitors are classified into two categories first one is tyrosine kinase inhibitor and the second one is monoclonal antibodies. Tyrosine kinase inhibitor binds to the area of tyrosine kinase in the epidermal growth factor receptor and hinders the activity of EGFR. Monoclonal antibodies bind to the extracellular components of EGFR prevent it to bind with its own receptor so that stop cell division. This review encompasses complete updates on a generation of epidermal growth factor receptor tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer. INTRODUCTION: Lung cancer is a very rapidly growing and serious disease worldwide. It is a primary cause of death globally. It is the most commonly diagnosed cancer with an annual death rate being over 1.3 million globally 1. In the year 2017, estimates suggested that, in North America alone, 222,500 new cases of lung cancer and 155,870 deaths occurred 2. Lung cancer is mainly divided into two groups i.e. small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer constituted about 75-80% of lung cancer and is further divided into three types adenocarcinoma (about 40%), squamous carcinoma (25-20%) and large-cell carcinoma (5-15%).

show abstract

“…The patients receiving dacomitinib had longer progression-free survival, but the treatment’s toxicity was higher. In the ongoing ARCHER 1050 study, dacomitinib is being compared with gefitinib as a first-line treatment for patients with advanced lung cancer [ 7 ].…”

Section: Egfr Tyrosine Kinase Inhibitors As a First-line Treatment Fomentioning

confidence: 99%

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years

Rybarczyk-Kasiuchnicz¹

2018

kitp

View full text Add to dashboard Cite

Lung cancer is the main cause of cancer-related deaths in Poland. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a new group of agents for non-small-cell lung cancer (NSCLC) patients. Determining the predictive value of activating mutations in the EGFR and ROS-1 genes and ALK rearrangement in non-small-cell lung cancer has enabled the identification of patients likely to achieve true clinical benefits. EGFR-TKIs may produce objective response in more than 60% of patients and prolong progression-free survival to 10 months in mutation-positive patients. No improvement of overall survival was shown in randomized trials. The era of immunotherapy implementing PD-1 and PD-L1 inhibitors has changed the face of lung cancer therapy. We aimed to review the literature on the use of EGFR-TKIs and immunotherapeutic agents for NSCLC patients.

show abstract

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Cited by 11 publications

References 37 publications

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors

Untitled

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years

Contact Info

Product

Resources

About